GlassScriptPhysician profile
Monica White
NPI 1235145558
$22,399.80
in general payments reported to CMS, 2019-2025
35 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,411 · 2022: $7,476 · 2023: $3,877 · 2024: $1,361 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395 · Consulting Fee: $2,450 · Honoraria: $1,050 · Travel and Lodging: $420 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.18 |
| Consulting Fee | $2,450.00 |
| Honoraria | $1,050.00 |
| Travel and Lodging | $419.77 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $15,173.68 | 2021-2025 | Myrisk, Colaris |
| Abbvie INC. | $1,763.31 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,577.45 | 2022-2025 | Datroway, Enhertu |
| Lilly USA, LLC | $1,103.85 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $461.48 | 2023-2025 | Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $317.83 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Pfizer INC. | $302.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $226.20 | 2022-2025 | Imjudo, Lynparza, Enhertu |
| Incyte Corporation | $222.96 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $174.26 | 2022-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $135.77 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.95 | 2024-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $89.66 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $75.64 | 2022-2025 | Tecvayli, Carvykti |
| Aveo Pharmaceuticals, INC. | $71.20 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.53 | 2024 | |
| Adaptive Biotechnologies Corporation | $57.98 | 2023-2024 | Clonoseq |
| Adc Therapeutics America, INC. | $50.53 | 2023 | |
| Astellas Pharma US INC | $46.79 | 2024-2025 | Vyloy, Xtandi |
| Seagen INC. | $45.46 | 2022 | |
| Sobi, INC | $42.75 | 2023-2024 | |
| Epizyme, INC. | $33.48 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $32.96 | 2024 | Onivyde |
| Geron Corporation | $25.59 | 2024 | Rytelo |
| Merck Sharp & Dohme LLC | $24.31 | 2024 | Keytruda |
| Servier Pharmaceuticals LLC | $20.74 | 2025 | |
| Karyopharm Therapeutics INC. | $20.33 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.57 | 2023 | |
| Array Biopharma INC | $19.43 | 2025 | Xalkori, Braftovi, Lorbrena |
| Morphosys, US INC. | $18.02 | 2022 | |
| Celgene Corporation | $16.28 | 2022 | |
| Csl Behring | $14.25 | 2023 | Kcentra |
| Tempus Ai, INC | $14.20 | 2025 | Xt Cdx |
| Blueprint Medicines Corporation | $13.58 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.